CollPlant shares fall 35.40% intraday after announcing $2 million registered direct offering and private placement.

CollPlant Biotechnologies (NASDAQ: CLGN) fell 35.4% intraday after announcing a registered direct offering and concurrent private placement to raise approximately $2.0 million through the issuance of 1.6 million ordinary shares and warrants. The offering, which includes dilutive warrants exercisable at $1.25 per share, triggered investor concerns over equity dilution and potential downward pressure on the stock. The proceeds will fund general corporate purposes, including R&D, but the significant issuance of new shares and warrants likely exacerbated selling pressure, aligning with the sharp intraday decline. The move reflects market skepticism about the company’s capital-raising strategy and its impact on shareholder value.